Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer | Zendy

Wilfried Eberhardt | Zendy; Paul Mitchell | Zendy; Joan H. Schiller | Zendy; Michael P. Brown | Zendy; Michael Thomas | Zendy; Glenn Mills | Zendy; Valentine Jehl | Zendy; Shweta Urva | Zendy; Jeffrey J. De Leo | Zendy; Sven Gogov | Zendy; Vassiliki A. Papadimitrakopoulou | Zendy

Open Access

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Author(s) -

Wilfried Eberhardt,

Paul Mitchell,

Joan H. Schiller,

Michael P. Brown,

Michael Thomas,

Glenn Mills,

Valentine Jehl,

Shweta Urva,

Jeffrey J. De Leo,

Sven Gogov,

Vassiliki A. Papadimitrakopoulou

Publication year - 2013

Publication title -

investigational new drugs

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.254

H-Index - 87

eISSN - 1573-0646

pISSN - 0167-6997

DOI - 10.1007/s10637-013-9958-3

Subject(s) - carboplatin , medicine , bevacizumab , everolimus , neutropenia , paclitaxel , febrile neutropenia , lung cancer , chemotherapy , oncology , pharmacology , urology , surgery , cisplatin

One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin ± bevacizumab. This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin ± bevacizumab for advanced NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research